Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Di Lu

Showing results (681-690 of 721) with videos related to

Pageof 73
Sort By:
British Journal of Cancer|February 10, 2024
Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacyHai-Shan Ye, Dan Zhou, Hong Li, et al.
Annals of the American Thoracic Society|March 3, 2022
Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association RegistryRoberto J Bernardo, Di Lu, Ramon L Ramirez, et al.
Lancet Regional Health. Americas|March 14, 2025
Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in BrazilMarco Antonio Moreira Puga, Roberto Dias de Oliveira, Patricia Vieira da Silva, et al.
Nature Communications|November 13, 2022
IL-33 induces thymic involution-associated naive T cell aging and impairs host control of severe infectionLei Xu, Chuan Wei, Ying Chen, et al.
Journal of Advanced Research|November 15, 2024
Oncogenic cholesterol rewires lipid metabolism in hepatocellular carcinoma via the CSNK2A1-IGF2R Ser2484 axisRen-Yi Su, Chen-Hao Xu, Hai-Jun Guo, et al.
Medcomm|August 27, 2024
An inflammatory liquid fingerprint predicting tumor recurrence after liver transplantation for hepatocellular carcinomaModan Yang, Zuyuan Lin, Li Zhuang, et al.
The Lancet Regional Health. Western Pacific|October 9, 2023
Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trialYong Huo, Beijian Chen, Qiufang Lian, et al.
JACC. Asia|August 24, 2023
Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 TrialLitong Qi, Dexue Liu, Yanling Qu, et al.
BMJ Public Health|July 7, 2025
Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in BrazilJuliana Barros Verruck, Marco Antonio Moreira Puga, Roberto Dias de Oliveira, et al.
Cell Chemical Biology|June 28, 2023
Chemical genomics reveals targetable programs of human cancers rooted in pluripotencyLuca Orlando, Yannick D Benoit, Jennifer C Reid, et al.
Pageof 73

Showing results (681-690 of 721) with videos related to

Sort By:
Pageof 73
British Journal of Cancer|February 10, 2024
Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacyHai-Shan Ye, Dan Zhou, Hong Li, et al.
Annals of the American Thoracic Society|March 3, 2022
Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association RegistryRoberto J Bernardo, Di Lu, Ramon L Ramirez, et al.
Lancet Regional Health. Americas|March 14, 2025
Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in BrazilMarco Antonio Moreira Puga, Roberto Dias de Oliveira, Patricia Vieira da Silva, et al.
Nature Communications|November 13, 2022
IL-33 induces thymic involution-associated naive T cell aging and impairs host control of severe infectionLei Xu, Chuan Wei, Ying Chen, et al.
Journal of Advanced Research|November 15, 2024
Oncogenic cholesterol rewires lipid metabolism in hepatocellular carcinoma via the CSNK2A1-IGF2R Ser2484 axisRen-Yi Su, Chen-Hao Xu, Hai-Jun Guo, et al.
Medcomm|August 27, 2024
An inflammatory liquid fingerprint predicting tumor recurrence after liver transplantation for hepatocellular carcinomaModan Yang, Zuyuan Lin, Li Zhuang, et al.
The Lancet Regional Health. Western Pacific|October 9, 2023
Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trialYong Huo, Beijian Chen, Qiufang Lian, et al.
JACC. Asia|August 24, 2023
Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 TrialLitong Qi, Dexue Liu, Yanling Qu, et al.
BMJ Public Health|July 7, 2025
Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in BrazilJuliana Barros Verruck, Marco Antonio Moreira Puga, Roberto Dias de Oliveira, et al.
Cell Chemical Biology|June 28, 2023
Chemical genomics reveals targetable programs of human cancers rooted in pluripotencyLuca Orlando, Yannick D Benoit, Jennifer C Reid, et al.
Pageof 73